{"id":"W2924781650","doi":"10.1111/bjd.17919","title":"Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials","year":2019,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Hidradenitis Suppurativa and Treatments","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Memorial University of Newfoundland","funders":"LEO Pharma; Eli Lilly and Company; AstraZeneca; Galderma; Medac; AbbVie; Regeneron Pharmaceuticals; Teva Pharmaceutical Industries; Celgene; Biogen; Gilead Sciences; Amgen; Pfizer","keywords":"Adalimumab; Medicine; Placebo; Dosing; Adverse effect; Hidradenitis suppurativa; Randomized controlled trial; Post-hoc analysis; Internal medicine; Clinical trial; Post hoc; Tumor necrosis factor alpha","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003073488,0.0004387927,0.005426773,0.0005058611,0.0001472869,0.0002281839,0.0003315457,0.0003629384,0.0008762334],"category_scores_gemma":[0.003398747,0.0003024751,0.0009000777,0.0005862533,0.0001831897,0.0004549487,0.00005011625,0.000988548,0.00006028842],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000174177,"about_ca_system_score_gemma":0.0007221766,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008304046,"about_ca_topic_score_gemma":0.0005873971,"domain_scores_codex":[0.9910622,0.003584575,0.003713351,0.0004445044,0.0006208475,0.0005745175],"domain_scores_gemma":[0.9915894,0.005880967,0.001392591,0.0003334387,0.0004554205,0.0003481696],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.770777,0.0007790859,0.000801864,0.00001587377,0.004212671,0.213528,0.001855145,0.00004335893,0.00108978,0.00004247528,0.001979975,0.004874784],"study_design_scores_gemma":[0.6609758,0.0002782245,0.0004106426,0.0006924109,0.001621733,0.3326311,0.00078629,0.001081792,0.001040809,0.0002073911,0.00005848098,0.0002154338],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9696208,0.002164871,0.0008781598,0.02143779,0.0006952113,0.003905919,0.0004223171,0.00003521387,0.0008397676],"genre_scores_gemma":[0.9979258,0.0004551974,0.0003250676,0.0001127481,0.0002045259,0.00008797134,0.0003930985,0.00004498096,0.0004506367],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.119103,"threshold_uncertainty_score":0.9999427,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02522170362663017,"score_gpt":0.3089418987806154,"score_spread":0.2837201951539852,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}